Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: Up-dated baseline data from randomized and multi-site clinical trials

Table 3 Treatment failures by Day 28 (adjusted by genotyping), stratified by age group

Treatment groups	No. of treatment failure/Total of Patients (%) [95% CI]
	Age groups		Significance level P*
	0.5 – 4 years	≥ 5 years
CQ	69/131 (52.6) [44.1–61.1]	63/169 (37.3) [30.2–44.7]	0.01
SP	8/171 (4.7) [2.2–8.7]	3/190 (1.6) [0.4–4.2]	0.57
AQ	4/174 (2.3) [0.7–5.5]	2/182 (1.1) [0.2–3.6]	0.64
ASAQ	4/161 (2.8) [0.8–5.9]	2/169 (1.2) [0.2–3.9]	0.51

CQ: Chloroquine; AQ: Amodiaquine; ASAQ: Artesunate + Amodiaquine; SP: Sulphadoxine-Pyrimethamine.
CI: Confidence Interval
Chi-square test for the comparison of two proportions

ISSN: 1475-2875